Edition:
United Kingdom

InVivo Therapeutics Holdings Corp (NVIV.OQ)

NVIV.OQ on NASDAQ Stock Exchange Global Market

0.98USD
8 Dec 2017
Change (% chg)

$0.03 (+3.17%)
Prev Close
$0.95
Open
$1.00
Day's High
$1.04
Day's Low
$0.95
Volume
35,233
Avg. Vol
26,124
52-wk High
$4.95
52-wk Low
$0.95

Select another date:

Fri, Nov 10 2017

Deals of the day-Mergers and acquisitions

Nov 10 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday:

French agricultural group InVivo to buy garden retailer Jardiland

PARIS French agricultural group InVivo has agreed to buy gardening chain Jardiland to strengthen its position in a sector drawing competitors from do-it-yourself stores to internet distributors.

French agricultural group InVivo to buy garden retailer Jardiland

PARIS French agricultural group InVivo has agreed to buy gardening chain Jardiland to strengthen its position in a sector drawing competitors from do-it-yourself stores to internet distributors.

UPDATE 1-French agricultural group InVivo to buy garden retailer Jardiland

* InVivo faces competition from mass retail, internet (Adds detail, CEO quote)

French agricultural group InVivo to buy gardening retail chain Jardiland

PARIS, Nov 10 French agricultural group InVivo said on Friday it was buying gardening chain Jardiland for an undisclosed amount as it expands its presence in retailing.

BRIEF-InVivo Therapeutics reports Q3 loss per share $0.28

* InVivo Therapeutics provides business update and reports 2017 third quarter financial results

France's InVivo in alliance talks with Jardiland gardening chain

PARIS, Oct 26 French agricultural cooperative InVivo's retail division is in exclusive talks over a potential alliance with gardening retailer Jardiland, the companies said on Thursday.

BRIEF-InVivo Therapeutics Holdings Corp - ‍ expects restructuring to be substantially completed by end of Q3 2017

* InVivo Therapeutics Holdings Corp - ‍ expects restructuring to be substantially completed by end of Q3 2017, to be fully completed by end of Q4 of 2017​

BRIEF-Invivo Therapeutics reports strategic corporate restructuring

* Invivo Therapeutics announces strategic corporate restructuring

BRIEF-InVivo Therapeutics Holdings Q2 adjusted loss per share $0.22 excluding items

* InVivo Therapeutics Holdings provides business update and reports 2017 second quarter financial results

Select another date: